TP53 and cancer: In addition, upregulation of YTHDF1 is frequently found in KRAS/TP53-mut LUAD patients and is associated with adverse prognosis; it functionally promotes cyclin B1 mRNA translation, thereby facilitating cancer cell proliferation by regulating the cell cycle pathway [38].